epithalon latest research 2025 or 2026 10mg Peptide Epithalon (AEDG) Telomerase & Epigenetic

(Frontiers in Pharmacology, 2022) reported pharmacokinetics and tissue distribution in rats and dogs, including a rapid plasma half-life under 30 minutes after IM or IV dosing

On the other hand, using non-recommended diluents like 0.9% sodium chloride injection can negatively impact the peptides stability and overall efficacy

In the event that impacted product is administered to a patient, there is an increased risk that severe adverse events, such as invasive bacterial infection, including bacterial meningitis, septicemia, and limited adverse events such as fever, chills, malaise, and cutaneous abscess may occur

Who Can Benefit